TGF-beta/Smad Compound Library

83 Cited Publications
Customer Review

Based on 83 publication(s) in Google Scholar

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 444 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

  • PDF
  • Excel
  • SDF
  • Manual

Service

Description & Advantages

•   A unique collection of 444 TGF-beta/Smad inhibitors for high throughput screening (HTS) and high content screening (HCS).

•   Targets include PKC, ROCK, TGF-beta/Smad, and TGF-β Receptor.

•   A useful tool for researching TGF-beta/Smad-related regulation and diseases.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   More detailed compound information with structure, IC50, and brief introduction.

•   NMR and HPLC validated to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 444 TGF-beta/Smad signaling related compounds supplied as pre-dissolved Solutions or Solid

Solution: 429 compounds supplied in 10 mM solution, 14 compounds supplied in 2 mM solution, 1 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage
-80°C
Shipping
Blue ice or dry ice

Documentation

  • PDF
  • Excel
  • SDF
  • Manual

Composition

PKC (138)

ROCK (79)

PKA (58)

RUNX (9)

Get a Quotation Now In-stock

Please select quantity
Amount: USD 0.00
Size
Price
Stock
Operate
Sample (0.1mg)
Free
In-stock
Estimated to ship on August 31 More
Apply Now
200 mg
USD 120
In-stock
Estimated to ship on August 31 More
500 mg
Get Quote
Consult sales personnel for more information
Bulk Inquiry
200 mg
USD 120
In-stock
Estimated to ship on August 31 More
500 mg
Get Quote
Consult sales personnel for more information
Bulk Inquiry
500 mg
Get Quote
Consult sales personnel for more information
Bulk Inquiry
Estimated to ship on August 31 More